Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company.The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management.
Samsung Biologics cell culture development process includes upstream, downstream and analytical technology.Samsung Biologics’ provides manufacturing and quality assurance for the clinical and commercial products.
The company also provides infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products.It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory.
Samsung Biologics is headquartered in Incheon, South Korea.
Samsung Biologics Co Ltd (207940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Regenerative Medicine Market Research Report by Type (Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule and Biologic, and Tissue-Engineered Products), by Application (Diabetes, Musculoskeletal Disorders, Ocular Disorders, Oncology, and Wound Care) - Global Forecast to 2025 - Cumulative Impact of...
The Allergy Immunotherapies market was valued at US$ million 1,819.18 in 2019 and is projected to reach US$ 4,185.89 million by 2027; it is expected to grow at a CAGR of 11.1% from 2020 to 2027. The growth of the allergy immunotherapies market is mainly attributed to factors such as growing prevalence of allergic disorders and technological...
The lyophilization services for biopharmaceuticals market was valued at US$ 702.06 million in 2019 and is projected to reach US$ 1,456.74 million by 2027; it is expected to grow at a CAGR of 9.7% during 2020-2027. The growth of the lyophilization services for biopharmaceuticals market is mainly attributed to factors such as rising demand...
Integrin Alpha 4 - Pipeline Review, H1 2020 Summary Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 18 molecules. The latest report Integrin Alpha 4 – Pipeline Review, H1 2020, outlays comprehensive information on...
Integrin Beta 7 - Pipeline Review, H1 2020 Summary Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium...
The bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a CAGR of 7.3% from 2020 to 2027. The increasing adoption of single-use bioreactors, and rapid growth of the pharmaceuticals and biotechnology industries are among the prime factors driving the...